Skip to main content
Home

Search form

  • ABOUT US
    • ECFS Society Details
      • Society Information
      • Applications for Support
    • ECFS Membership
      • Membership Subscription
      • Membership Demographics
    • Other Information
      • Latest News
      • Job Opportunities
      • Grants and Programmes
      • Links
  • RESEARCH
    • ECFS Projects
      • ECFS Clinical Trials Network
      • ECFS Patient Registry
    • ECFS Working Groups
      • Diagnostic Network
      • Exercise
      • Neonatal Screening
      • Fungal Pathogens
      • Pulmonary Exacerbation
    • Special Projects
      • ECFS / CF Europe Post-Doctoral Research Fellowship
      • CFQ-R questionnaire and CF candidates for lung transplant
      • EU funded projects
      • MucoFong International Project
      • Complete CFTR gene mutation analysis in European patients with Cystic Fibrosis
    • Past Working Groups
      • Cystic Fibrosis Molecular and Cell Biology and Physiology Basic Science
      • ECFS Gene Modifier Working Group
      • ECFS Non Tuberculous Mycobacteria Working Group
  • CARE
    • ECFS Standards Of Care
    • ECFS Working Groups
      • Exercise
      • Diagnostic Network
      • Neonatal Screening
      • Mental Health
      • Fungal Pathogens
      • Pulmonary Exacerbation
      • Telehealth
    • Allied Health Professionals
      • ECFS Nursing Special interest Group
      • European CF Pharmacy Group
      • European Cystic Fibrosis Nutrition Group
      • European Psychosocial Special Interest Group
      • ECFS Physiotherapy Special Interest International Group
  • EDUCATION
  • CONFERENCES & EVENTS
    • European Cystic Fibrosis Conference
    • ECFS Basic Science Conference
    • Related events
    • Past ECFS conferences
  • PUBLICATIONS
    • About Publications
      • The Journal of Cystic Fibrosis
      • ECFS Newsletter
      • ECFS Book
      • ERS Monograph
    • Resources
      • Search All Resources
      • CF Research News
      • Consensus Reports
      • ECFS Guidelines
      • Free Access Articles
      • CF Literature
  • MEMBERSHIP
  • LOG IN

Other Guidelines

A review of research about Trikafta and mental health: a report from Cystic Fibrosis Foundation’s Prioritizing Research in Mental Health Working Group

  • Read more about A review of research about Trikafta and mental health: a report from Cystic Fibrosis Foundation’s Prioritizing Research in Mental Health Working Group

The relation between the physical activity behaviour of youth with Cystic Fibrosis and their parents

  • Read more about The relation between the physical activity behaviour of youth with Cystic Fibrosis and their parents

Elexacaftor/tezacaftor/ivacaftor can be effective for people with cystic fibrosis with the 3849 gene variant

  • Read more about Elexacaftor/tezacaftor/ivacaftor can be effective for people with cystic fibrosis with the 3849 gene variant

Daily changes in the amount of Pseudomonas in CF sputum

  • Read more about Daily changes in the amount of Pseudomonas in CF sputum

Use of Elexacaftor/Tezacaftor/Ivacaftor in Pregnant Mothers without CF to Treat Meconium Ileus in Fetuses with Cystic Fibrosis

  • Read more about Use of Elexacaftor/Tezacaftor/Ivacaftor in Pregnant Mothers without CF to Treat Meconium Ileus in Fetuses with Cystic Fibrosis

Effect of elexacaftor/tezacaftor/ivacaftor on the use of routine therapies in Danish people with cystic fibrosis

  • Read more about Effect of elexacaftor/tezacaftor/ivacaftor on the use of routine therapies in Danish people with cystic fibrosis

Coping and Learning to Manage Stress (CALM): A telehealth intervention to help reduce depression and anxiety symptoms in adults with CF

  • Read more about Coping and Learning to Manage Stress (CALM): A telehealth intervention to help reduce depression and anxiety symptoms in adults with CF

What do people with CF think about their health since starting ETI?

  • Read more about What do people with CF think about their health since starting ETI?

A mouse model containing the W1282X mutation can be used to test cystic fibrosis therapies

  • Read more about A mouse model containing the W1282X mutation can be used to test cystic fibrosis therapies

Understanding rates of and factors associated with elexacaftor/tezacaftor/ivacaftor (ETI) prescription

  • Read more about Understanding rates of and factors associated with elexacaftor/tezacaftor/ivacaftor (ETI) prescription
  • first
  • previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next
  • last
Terms & Conditions Privacy policy  Accessibility Sitemap Contact 
© EUROPEAN CYSTIC FIBROSIS SOCIETY 2025. All rights reserved. Website by VidaVia (link is external)
European Cystic Fibrosis Society (ECFS)